U.S. markets close in 5 hours 34 minutes
  • S&P 500

    3,460.23
    +17.11 (+0.50%)
     
  • Dow 30

    28,424.25
    +115.46 (+0.41%)
     
  • Nasdaq

    11,586.75
    +70.25 (+0.61%)
     
  • Russell 2000

    1,620.93
    +3.22 (+0.20%)
     
  • Crude Oil

    41.06
    -0.64 (-1.53%)
     
  • Gold

    1,931.60
    +16.20 (+0.85%)
     
  • Silver

    25.30
    +0.32 (+1.28%)
     
  • EUR/USD

    1.1872
    +0.0044 (+0.37%)
     
  • 10-Yr Bond

    0.8160
    +0.0190 (+2.38%)
     
  • GBP/USD

    1.3138
    +0.0191 (+1.47%)
     
  • USD/JPY

    104.4940
    -0.9760 (-0.93%)
     
  • BTC-USD

    12,607.65
    +1,550.64 (+14.02%)
     
  • CMC Crypto 200

    250.68
    +5.79 (+2.36%)
     
  • FTSE 100

    5,811.98
    -77.24 (-1.31%)
     
  • Nikkei 225

    23,639.46
    +72.42 (+0.31%)
     

If You Had Bought Akebia Therapeutics (NASDAQ:AKBA) Stock A Year Ago, You Could Pocket A 132% Gain Today

Simply Wall St
·3 mins read

While Akebia Therapeutics, Inc. (NASDAQ:AKBA) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 15% in the last quarter. Despite this, the stock is a strong performer over the last year, no doubt about that. Like an eagle, the share price soared 132% in that time. So some might not be surprised to see the price retrace some. Investors should be wondering whether the business itself has the fundamental value required to continue to drive gains.

View our latest analysis for Akebia Therapeutics

Akebia Therapeutics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Akebia Therapeutics grew its revenue by 19% last year. We respect that sort of growth, no doubt. While that revenue growth is pretty good the share price performance outshone it, with a lift of 132% as mentioned above. If the profitability is on the horizon then now could be a very exciting time to be a shareholder. Of course, we are always cautious about succumbing to 'fear of missing out' when a stock has shot up strongly.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

earnings-and-revenue-growth
earnings-and-revenue-growth

We consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. If you are thinking of buying or selling Akebia Therapeutics stock, you should check out this free report showing analyst profit forecasts.

A Different Perspective

It's good to see that Akebia Therapeutics has rewarded shareholders with a total shareholder return of 132% in the last twelve months. That's better than the annualised return of 7.9% over half a decade, implying that the company is doing better recently. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - Akebia Therapeutics has 3 warning signs we think you should be aware of.

Akebia Therapeutics is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.